Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats

BACKGROUND: Antineoplastic drug cisplatin remains the drug of choice for various solid tumours including breast cancer. But dose dependent nephrotoxicity is the major drawback in majority of platinum based chemotherapy regimens. Recent reports have shown that inflammatory pathways are the main offen...

Descripción completa

Detalles Bibliográficos
Autores principales: Tikoo, Kulbhushan, Kumar, Parveen, Gupta, Jeena
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676298/
https://www.ncbi.nlm.nih.gov/pubmed/19356226
http://dx.doi.org/10.1186/1471-2407-9-107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676298/
https://www.ncbi.nlm.nih.gov/pubmed/19356226
http://dx.doi.org/10.1186/1471-2407-9-107

Ejemplares similares